Is BPC-157 in Human Clinical Trials? What NCT07803250 Actually Shows
The concise answer
Short answer: A new BPC-157 human trial record, NCT07803250, describes a planned University of Arkansas Phase 1 study after rotator-cuff repair. As of September 4, 2026, it is not yet recruiting, has an estimated January 2027 start, and has no results. Other human-study records also exist, so this is not the first BPC-157 trial. The new record also contains unresolved inconsistencies about enrollment, masking, the comparator, and the outcomes that would be measured.
That makes this a development worth watching—not evidence of safety, effectiveness, FDA approval, or a completed clinical trial.
Last reviewed: September 4, 2026. Trial status and registry fields can change.
What is NCT07803250?
The record, first posted to ClinicalTrials.gov on September 3, describes an early pilot study in adults undergoing arthroscopic rotator-cuff repair. The University of Arkansas is listed as sponsor, and the University of Arkansas for Medical Sciences Medical Center in Little Rock is the listed study site.
| Registry field | Current public listing |
|---|---|
| Official title | Impact of BPC-157 on Recovery From Rotator Cuff Repair Surgery |
| Study type | Interventional, Phase 1 |
| Status | Not yet recruiting |
| Sponsor | University of Arkansas |
| Location | University of Arkansas for Medical Sciences Medical Center, Little Rock |
| Structured enrollment | 30 estimated; the narrative summary says 20 |
| Estimated start | January 1, 2027 |
| Estimated completion | August 1, 2027 |
| Results | None posted |
These dates and design details are submitted registry information, not completed milestones. “Estimated” means they may change, and “not yet recruiting” means the study is not currently listed as open for enrollment.
What does the study plan to test?
The registry describes a randomized study comparing a BPC-157 group with a comparator group after rotator-cuff surgery. The BPC-157 arm is described as using a subcutaneous injection once daily for 90 days alongside standard postoperative rehabilitation.
The public record does not identify the dose, concentration, manufacturer, source, molecular form, or analytical specifications of the planned BPC-157 intervention. Those omissions matter. A registry entry is not an administration guide, and it should never be used to support self-experimentation.
The structured outcomes module currently lists shoulder strength as its only primary outcome, measured with a handheld dynamometer at baseline, 12 weeks, and five months. The narrative summary additionally mentions MRI assessment, patient-reported outcomes, range of motion, muscle strength, collagen-turnover biomarkers, inflammation biomarkers, safety, and feasibility. Those additional measures are not currently represented as structured outcomes.
Why the registry record needs a careful reading
The first public version contains several material inconsistencies:
- Enrollment: the structured field says 30 participants, while the summary says 20.
- Masking: the structured design says quadruple masking, while the summary calls the study double-blind.
- Comparator: the summary and arm description say the comparator group would self-administer saline injections daily for 90 days. Another intervention description says the sham group would receive no placebo injections.
- Outcomes: the summary describes MRI, patient-reported, range-of-motion, biomarker, safety, and feasibility assessments, while the structured module lists only shoulder strength.
- Intervention details: no dose, formulation, manufacturer, or product-quality specifications are posted.
These conflicts do not prove that the proposed research is invalid. New records can be corrected or expanded. They do mean that readers should not present the exact sample size, blinding arrangement, comparator design, or outcome plan as settled until the sponsor clarifies the record.
Is this the first human BPC-157 trial?
No. NCT07803250 should not be described as the first human BPC-157 trial or the first registered Phase 1 study.
ClinicalTrials.gov currently includes other records that mention BPC-157:
- NCT02637284, first posted in 2015, describes a randomized Phase 1 oral safety and pharmacokinetics study in healthy volunteers. Its current status is unknown, and no results are posted.
- NCT07437547 describes a Phase 2 study in acute hamstring strain. The registry lists it as recruiting, with no results posted.
- NCT07752381 describes a single-group study of a gummy product reported to contain BPC-157. It is marked completed, but no results are posted.
FDA’s July 2026 review materials also summarized limited prior human exposure reports and small studies. The careful, supportable statement is narrower: NCT07803250 appears to be the first ClinicalTrials.gov record specifically focused on BPC-157 following rotator-cuff repair. It is not the beginning of all human investigation.
For a broader look at published human, animal, in-vitro, and analytical literature, see our BPC-157 research evidence overview.
Does “Phase 1” mean BPC-157 has been shown to work?
No. Phase 1 is an early stage of clinical research. FDA explains that Phase 1 studies generally focus on safety, dosage, how an investigational drug behaves in the body, and information needed to guide later research. NCT07803250 includes functional measures in surgical patients, but its phase designation does not establish clinical benefit.
More importantly, this particular study has no results. A planned endpoint is a question the investigators intend to measure; it is not an outcome that has already occurred.
Does the ClinicalTrials.gov listing mean FDA approved the study or BPC-157?
No. ClinicalTrials.gov explains that study information is submitted by sponsors and investigators, who are responsible for its safety, science, and accuracy. A listing is not a U.S. government endorsement or a finding that the intervention is safe or effective. See the official ClinicalTrials.gov disclaimer.
The NCT07803250 record marks the study as involving an “FDA-regulated drug.” That is a sponsor-submitted regulatory-scope field—not marketing approval, FDA endorsement, or public proof of a particular Investigational New Drug application.
In July 2026, FDA presented a review of BPC-157-related bulk drug substances to its Pharmacy Compounding Advisory Committee. FDA said clinical safety information was insufficient and discussed concerns involving substance identity, impurities, aggregation, and potential immunogenicity. The agency also stated that neither BPC-157 free base nor BPC-157 acetate was a component of an FDA-approved drug at that time. Readers can review the agency’s full meeting materials and JD BioWorks’ separate explanation of the 2026 peptide-compounding discussion.
A trial registration and a drug approval are different regulatory events. Registration does not authorize general consumer or clinical use.
What should researchers watch next?
The most meaningful future signals would be:
- A verified change from “not yet recruiting” to “recruiting.”
- Confirmation that participant enrollment has actually begun.
- Resolution of the 30-versus-20 enrollment discrepancy.
- A consistent description of masking and the comparator group.
- Disclosure of dose, formulation, source, and product specifications.
- A complete set of prespecified safety and efficacy outcomes.
- A posted protocol, statistical analysis plan, results submission, or peer-reviewed report.
Until then, NCT07803250 is best understood as a newly registered research plan.
Frequently asked questions
Is NCT07803250 recruiting participants now?
No. As of September 4, 2026, ClinicalTrials.gov lists it as not yet recruiting. The start date is estimated as January 1, 2027.
Is NCT07803250 a Phase 2 trial?
No. Its structured registry record identifies it as Phase 1. A separate record, NCT07437547, describes a Phase 2 BPC-157 hamstring-strain study.
Are there results from the rotator-cuff study?
No. The study is not yet recruiting and the registry has no posted results.
Does the registry show that BPC-157 is safe or effective?
No. It describes a proposed study. Conclusions about safety or effectiveness require completed research, adequate analysis, and appropriate scientific and regulatory review.
The bottom line
NCT07803250 is a meaningful new record because it describes a planned U.S. Phase 1 investigation of BPC-157 after rotator-cuff repair. The precise interpretation is equally important: the study is not yet recruiting, has no results, omits key intervention details, and contains unresolved internal inconsistencies.
The registry creates a research question. It does not answer it.
Explore the JD BioWorks Research Library for source-linked explanations of peptide evidence, clinical-trial records, and regulatory developments. Our methods are described in our Scientific Sourcing and Editorial Standards.
Primary sources
- ClinicalTrials.gov: NCT07803250.
- ClinicalTrials.gov: NCT02637284.
- ClinicalTrials.gov: NCT07437547.
- ClinicalTrials.gov: NCT07752381.
- National Library of Medicine: ClinicalTrials.gov disclaimer.
- U.S. Food and Drug Administration: July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting materials.
Research-use and editorial disclaimer: This article summarizes publicly available study-registry and regulatory information for educational purposes. It is not medical advice, treatment guidance, or a recommendation to use BPC-157. JD BioWorks materials are intended solely for qualified laboratory research and are not for human or veterinary use. A clinical-trial record must never be used as a guide for self-administration. Review the full research-use disclaimer.
Related Research Materials
BPC-157
BPC-157 10 mg research material. Lot-specific analytical documentation is available below.
View Research Material
GLOW 70 mg Research Blend
GLOW 70 mg research blend. Labeled formulation: GHK-Cu 50 mg, BPC-157 10 mg, and TB-4 10 mg. Lot-specific…
View Research Material
KLOW 80 mg Research Blend
KLOW 80 mg research blend labeled GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10…
View Research Material